| |
|
|
|
|
| Slide Lecture Programs |
| 2006 Core Curriculum |
| Antiplatelet Interventions in ACS |
March 10, 2006
|
| VI: |
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence
- STEMI continues to be a major public health problem although considerable improvement has occurred in the care of patients.
- All patients with STEMI should undergo rapid evaluation for reperfusion therapy, which can be accomplished by pharmacologic (fibrinolysis) or catheter-based (primary PCI) approaches.
- The role of GP IIb/IIIa inhibitors as an adjunctive therapy in patients with STEMI who undergo primary PCI is continuing to evolve as evidence from clinical trials increases.
|
|
|
Resources